Anna Marie Mulligan

List of Publications by Year in Descending Order

111 papers	9,268 citations	46 h-index	96 g-index
120 ext. papers	11,425 ext. citations	10.9 avg, IF	4.35 L-index

#	Paper	IF	Citations
111	Contralateral Breast Screening with Preoperative MRI: Long-Term Outcomes for Newly Diagnosed Breast Cancer.. *Radiology*, **2022**, 212361	20.5	1
110	The predictive ability of the 313 variant-based polygenic risk score for contralateral breast cancer risk prediction in women of European ancestry with a heterozygous BRCA1 or BRCA2 pathogenic variant. *Genetics in Medicine*, **2021**, 23, 1726-1737	8.1	2
109	Breast Cancer Risk Genes - Association Analysis in More than 113,000 Women. *New England Journal of Medicine*, **2021**, 384, 428-439	59.2	143
108	Association of germline genetic variants with breast cancer-specific survival in patient subgroups defined by clinic-pathological variables related to tumor biology and type of systemic treatment. *Breast Cancer Research*, **2021**, 23, 86	8.3	1
107	The characteristics associated with upgrade on surgical pathology of conventional imaging occult DCIS diagnosed by MRI. *Breast Cancer Research and Treatment*, **2021**, 190, 317-327	4.4	
106	Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses. *Nature Genetics*, **2020**, 52, 572-581	36.3	76
105	Patterns of Recurrence and Predictors of Survival in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy, Surgery, and Radiation. *International Journal of Radiation Oncology Biology Physics*, **2020**, 108, 676-685	4	0
104	Germline HOXB13 mutations p.G84E and p.R217C do not confer an increased breast cancer risk. *Scientific Reports*, **2020**, 10, 9688	4.9	2
103	Characterization of the Cancer Spectrum in Men With Germline BRCA1 and BRCA2 Pathogenic Variants: Results From the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). *JAMA Oncology*, **2020**, 6, 1218-1230	13.4	25
102	A network analysis to identify mediators of germline-driven differences in breast cancer prognosis. *Nature Communications*, **2020**, 11, 312	17.4	20
101	Association of Genomic Domains in and with Prostate Cancer Risk and Aggressiveness. *Cancer Research*, **2020**, 80, 624-638	10.1	22
100	Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes. *Nature Genetics*, **2020**, 52, 56-73	36.3	56
99	Predictors of Outcome in Mammary Adenoid Cystic Carcinoma: A Multi-Institutional Study. *American Journal of Surgical Pathology*, **2020**, 44, 214-223	6.7	14
98	Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants. *Genetics in Medicine*, **2020**, 22, 1653-1666	8.1	34
97	Breast Cancer Polygenic Risk Score and Contralateral Breast Cancer Risk. *American Journal of Human Genetics*, **2020**, 107, 837-848	11	12
96	Two truncating variants in FANCC and breast cancer risk. *Scientific Reports*, **2019**, 9, 12524	4.9	2
95	Shared heritability and functional enrichment across six solid cancers. *Nature Communications*, **2019**, 10, 431	17.4	45

94	Breast specimen handling and reporting in the post-neoadjuvant setting: challenges and advances. *Journal of Clinical Pathology*, **2019**, 72, 120-132	3.9	13
93	Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer. *Nature Communications*, **2019**, 10, 1741	17.4	47
92	Genome-wide association study of germline variants and breast cancer-specific mortality. *British Journal of Cancer*, **2019**, 120, 647-657	8.7	28
91	Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes. *American Journal of Human Genetics*, **2019**, 104, 21-34	11	363
90	Associations of obesity and circulating insulin and glucose with breast cancer risk: a Mendelian randomization analysis. *International Journal of Epidemiology*, **2019**, 48, 795-806	7.8	52
89	Fresh Cut Versus Stored Cut Paraffin-embedded Tissue: Effect on Immunohistochemical Staining for Common Breast Cancer Markers. *Applied Immunohistochemistry and Molecular Morphology*, **2019**, 27, 231-237	1.9	5
88	Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations. *Human Mutation*, **2018**, 39, 593-620	4.7	138
87	Tumoral BRD4 expression in lymph node-negative breast cancer: association with T-bet+ tumor-infiltrating lymphocytes and disease-free survival. *BMC Cancer*, **2018**, 18, 750	4.8	7
86	A transcriptome-wide association study of 229,000 women identifies new candidate susceptibility genes for breast cancer. *Nature Genetics*, **2018**, 50, 968-978	36.3	101
85	Assessment of PD-L1 expression across breast cancer molecular subtypes, in relation to mutation rate, -like status, tumor-infiltrating immune cells and survival. *OncoImmunology*, **2018**, 7, e1509820	7.2	51
84	Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. *Nature Genetics*, **2017**, 49, 680-691	36.3	190
83	Association analysis identifies 65 new breast cancer risk loci. *Nature*, **2017**, 551, 92-94	50.4	643
82	Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. *Nature Genetics*, **2017**, 49, 1767-1778	36.3	186
81	Prediction of Breast and Prostate Cancer Risks in Male BRCA1 and BRCA2 Mutation Carriers Using Polygenic Risk Scores. *Journal of Clinical Oncology*, **2017**, 35, 2240-2250	2.2	101
80	Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3. *Breast Cancer Research and Treatment*, **2017**, 161, 117-134	4.4	15
79	Body mass index and breast cancer survival: a Mendelian randomization analysis. *International Journal of Epidemiology*, **2017**, 46, 1814-1822	7.8	27
78	- a novel candidate breast cancer susceptibility locus on 6q14.1. *Oncotarget*, **2017**, 8, 102769-102782	3.3	3
77	No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. *Gynecologic Oncology*, **2016**, 141, 386-401	4.9	15

76	Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus. *Nature Communications*, **2016**, 7, 12675	17.4	53
75	Validation of Intratumoral T-bet+ Lymphoid Cells as Predictors of Disease-Free Survival in Breast Cancer. *Cancer Immunology Research*, **2016**, 4, 41-8	12.5	18
74	Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170. *Nature Genetics*, **2016**, 48, 374-86	36.3	93
73	PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS. *Journal of Medical Genetics*, **2016**, 53, 800-811	5.8	121
72	Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus. *Breast Cancer Research*, **2016**, 18, 64	8.3	25
71	Genetic predisposition to ductal carcinoma in situ of the breast. *Breast Cancer Research*, **2016**, 18, 22	8.3	31
70	Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2. *Breast Cancer Research*, **2016**, 18, 15	8.3	58
69	Identification of six new susceptibility loci for invasive epithelial ovarian cancer. *Nature Genetics*, **2015**, 47, 164-71	36.3	177
68	Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer. *Nature Genetics*, **2015**, 47, 373-80	36.3	406
67	Identification of novel genetic markers of breast cancer survival. *Journal of the National Cancer Institute*, **2015**, 107,	9.7	38
66	Menacalc, a quantitative method of metastasis assessment, as a prognostic marker for axillary node-negative breast cancer. *BMC Cancer*, **2015**, 15, 483	4.8	22
65	Candidate genetic modifiers for breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers. *Cancer Epidemiology Biomarkers and Prevention*, **2015**, 24, 308-16	4	20
64	Investigation of gene-environment interactions between 47 newly identified breast cancer susceptibility loci and environmental risk factors. *International Journal of Cancer*, **2015**, 136, E685-96	7.5	26
63	An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers. *Breast Cancer Research*, **2015**, 17, 61	8.3	16
62	Common germline polymorphisms associated with breast cancer-specific survival. *Breast Cancer Research*, **2015**, 17, 58	8.3	24
61	Prediction of breast cancer risk based on profiling with common genetic variants. *Journal of the National Cancer Institute*, **2015**, 107,	9.7	324
60	Germline mutation in BRCA1 or BRCA2 and ten-year survival for women diagnosed with epithelial ovarian cancer. *Clinical Cancer Research*, **2015**, 21, 652-7	12.9	107
59	A large-scale assessment of two-way SNP interactions in breast cancer susceptibility using 46,450 cases and 42,461 controls from the breast cancer association consortium. *Human Molecular Genetics*, **2014**, 23, 1934-46	5.6	28

58	Genetic variation in mitotic regulatory pathway genes is associated with breast tumor grade. *Human Molecular Genetics*, **2014**, 23, 6034-46	5.6	11
57	Genetic variation at CYP3A is associated with age at menarche and breast cancer risk: a case-control study. *Breast Cancer Research*, **2014**, 16, R51	8.3	12
56	MicroRNA related polymorphisms and breast cancer risk. *PLoS ONE*, **2014**, 9, e109973	3.7	37
55	Genetic predisposition to in situ and invasive lobular carcinoma of the breast. *PLoS Genetics*, **2014**, 10, e1004285	6	38
54	DNA glycosylases involved in base excision repair may be associated with cancer risk in BRCA1 and BRCA2 mutation carriers. *PLoS Genetics*, **2014**, 10, e1004256	6	33
53	Current morphologic criteria perform poorly in identifying hereditary leiomyomatosis and renal cell carcinoma syndrome-associated uterine leiomyomas. *International Journal of Gynecological Pathology*, **2014**, 33, 560-7	3.2	21
52	Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers. *Breast Cancer Research*, **2014**, 16, 3416	8.3	46
51	Clinical-pathologic significance of cancer stem cell marker expression in familial breast cancers. *Breast Cancer Research and Treatment*, **2013**, 140, 195-205	4.4	35
50	Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. *Nature Genetics*, **2013**, 45, 371-84, 384e1-2	36.3	422
49	Elevated expression of podocalyxin is associated with lymphatic invasion, basal-like phenotype, and clinical outcome in axillary lymph node-negative breast cancer. *Breast Cancer Research and Treatment*, **2013**, 137, 709-19	4.4	24
48	Functional variants at the 11q13 risk locus for breast cancer regulate cyclin D1 expression through long-range enhancers. *American Journal of Human Genetics*, **2013**, 92, 489-503	11	167
47	Genome-wide association studies identify four ER negative-specific breast cancer risk loci. *Nature Genetics*, **2013**, 45, 392-8, 398e1-2	36.3	327
46	Large-scale genotyping identifies 41 new loci associated with breast cancer risk. *Nature Genetics*, **2013**, 45, 353-61, 361e1-2	36.3	813
45	Genetic modifiers of menopausal hormone replacement therapy and breast cancer risk: a genome-wide interaction study. *Endocrine-Related Cancer*, **2013**, 20, 875-87	5.7	19
44	Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk. *PLoS Genetics*, **2013**, 9, e1003212	6	209
43	Evidence of gene-environment interactions between common breast cancer susceptibility loci and established environmental risk factors. *PLoS Genetics*, **2013**, 9, e1003284	6	112
42	Tumoral lymphocytic infiltration and expression of the chemokine CXCL10 in breast cancers from the Ontario Familial Breast Cancer Registry. *Clinical Cancer Research*, **2013**, 19, 336-46	12.9	91
41	Met synergizes with p53 loss to induce mammary tumors that possess features of claudin-low breast cancer. *Proceedings of the National Academy of Sciences of the United States of America*, **2013**, 110, E1301-10	11.5	58

40	Histological and immunohistochemical features to distinguish between adipocyte hyperplasia, atrophy and neoplasia: differential diagnosis of small round adipocytes in Crohn's disease. *Histopathology*, **2012**, 61, 984-5	7.3	1
39	Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2 mutation carriers. *Breast Cancer Research*, **2012**, 14, R33	8.3	70
38	Comparison of clinical schemas and morphologic features in predicting Lynch syndrome in mutation-positive patients with endometrial cancer encountered in the context of familial gastrointestinal cancer registries. *Cancer*, **2012**, 118, 681-8	6.4	62
37	Risk factors for uncommon histologic subtypes of breast cancer using centralized pathology review in the Breast Cancer Family Registry. *Breast Cancer Research and Treatment*, **2012**, 134, 1209-20	4.4	9
36	Genome-wide association analysis identifies three new breast cancer susceptibility loci. *Nature Genetics*, **2012**, 44, 312-8	36.3	237
35	9q31.2-rs865686 as a susceptibility locus for estrogen receptor-positive breast cancer: evidence from the Breast Cancer Association Consortium. *Cancer Epidemiology Biomarkers and Prevention*, **2012**, 21, 1783-91	4	17
34	11q13 is a susceptibility locus for hormone receptor positive breast cancer. *Human Mutation*, **2012**, 33, 1123-32	4.7	33
33	19p13.1 is a triple-negative-specific breast cancer susceptibility locus. *Cancer Research*, **2012**, 72, 1795-803	8.1	93
32	Common variants at the 19p13.1 and ZNF365 loci are associated with ER subtypes of breast cancer and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers. *Cancer Epidemiology Biomarkers and Prevention*, **2012**, 21, 645-57	4	44
31	Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). *Cancer Epidemiology Biomarkers and Prevention*, **2012**, 21, 134-47	4	411
30	Use of mismatch repair immunohistochemistry and microsatellite instability testing: exploring Canadian practices. *American Journal of Surgical Pathology*, **2012**, 36, 560-9	6.7	22
29	Papillary lesions of the breast: impact of breast pathology subspecialization on core biopsy and excision diagnoses. *American Journal of Surgical Pathology*, **2012**, 36, 544-51	6.7	44
28	Comparison of 6q25 breast cancer hits from Asian and European Genome Wide Association Studies in the Breast Cancer Association Consortium (BCAC). *PLoS ONE*, **2012**, 7, e42380	3.7	49
27	Contribution of large genomic BRCA1 alterations to early-onset breast cancer selected for family history and tumour morphology: a report from The Breast Cancer Family Registry. *Breast Cancer Research*, **2011**, 13, R14	8.3	9
26	Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2. *Breast Cancer Research*, **2011**, 13, R110	8.3	62
25	Histologic artifacts in abdominal, vaginal, laparoscopic, and robotic hysterectomy specimens: a blinded, retrospective review. *American Journal of Surgical Pathology*, **2011**, 35, 115-26	6.7	59
24	Müllerian adenosarcomas with unusual growth patterns: staging issues. *International Journal of Gynecological Pathology*, **2011**, 30, 340-7	3.2	15
23	EMSY and CCND1 amplification in familial breast cancer: from the Ontario site of the Breast Cancer Family Registry. *Breast Cancer Research and Treatment*, **2011**, 127, 831-9	4.4	6

22	CK8/18 expression, the basal phenotype, and family history in identifying BRCA1-associated breast cancer in the Ontario site of the breast cancer family registry. *Cancer*, **2011**, 117, 1350-9	6.4	12
21	Confirmation of 5p12 as a susceptibility locus for progesterone-receptor-positive, lower grade breast cancer. *Cancer Epidemiology Biomarkers and Prevention*, **2011**, 20, 2222-31	4	27
20	Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies. *Journal of the National Cancer Institute*, **2011**, 103, 250-63	9.7	513
19	Low penetrance breast cancer susceptibility loci are associated with specific breast tumor subtypes: findings from the Breast Cancer Association Consortium. *Human Molecular Genetics*, **2011** , 20, 3289-303	5.6	140
18	Associations of common variants at 1p11.2 and 14q24.1 (RAD51L1) with breast cancer risk and heterogeneity by tumor subtype: findings from the Breast Cancer Association Consortium. *Human Molecular Genetics*, **2011**, 20, 4693-706	5.6	66
17	The effect of prolonged fixation on the immunohistochemical evaluation of estrogen receptor, progesterone receptor, and HER2 expression in invasive breast cancer: a prospective study. *American Journal of Surgical Pathology*, **2011**, 35, 545-52	6.7	54
16	Invasive lobular carcinoma of the breast presenting as retroperitoneal fibrosis: a case report. *Journal of Medical Case Reports*, **2010**, 4, 175	1.2	12
15	Endometrial giant cell carcinoma: a case series and review of the spectrum of endometrial neoplasms containing giant cells. *American Journal of Surgical Pathology*, **2010**, 34, 1132-8	6.7	14
14	Cytokeratin 5 and estrogen receptor immunohistochemistry as a useful adjunct in identifying atypical papillary lesions on breast needle core biopsy. *American Journal of Surgical Pathology*, **2009** , 33, 1615-23	6.7	44
13	Encapsulated Papillary Carcinoma of the Breast. *Surgical Pathology Clinics*, **2009**, 2, 319-50	3.9	3
12	Prognostic effect of basal-like breast cancers is time dependent: evidence from tissue microarray studies on a lymph node-negative cohort. *Clinical Cancer Research*, **2008**, 14, 4168-74	12.9	35
11	JAG1 expression is associated with a basal phenotype and recurrence in lymph node-negative breast cancer. *Breast Cancer Research and Treatment*, **2008**, 111, 439-48	4.4	123
10	High-level JAG1 mRNA and protein predict poor outcome in breast cancer. *Modern Pathology*, **2007**, 20, 685-93	9.8	168
9	Insulin receptor is an independent predictor of a favorable outcome in early stage breast cancer. *Breast Cancer Research and Treatment*, **2007**, 106, 39-47	4.4	83
8	Metastatic potential of encapsulated (intracystic) papillary carcinoma of the breast: a report of 2 cases with axillary lymph node micrometastases. *International Journal of Surgical Pathology*, **2007**, 15, 143-7	1.2	81
7	Papillary lesions of the breast: a review. *Advances in Anatomic Pathology*, **2007**, 14, 108-19	5.1	96
6	PGDS, a novel technique combining chromogenic in situ hybridization and immunohistochemistry for the assessment of ErbB2 (HER2/neu) status in breast cancer. *Applied Immunohistochemistry and Molecular Morphology*, **2007**, 15, 316-24	1.9	15
5	Fibroepithelial Lesions, Including Fibroadenoma and Phyllodes Tumor **2006**, 109-124		1

4	Diseases of the Nipple **2006**, 139-148	1
3	Sclerosing polycystic sialadenopathy: a rare cause of recurrent tumor of the parotid gland. *JAMA Otolaryngology*, **2004**, 130, 357-60	21
2	Fine-mapping of 150 breast cancer risk regions identifies 178 high confidence target genes	2
1	Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses	2